Literature DB >> 18637505

Nuts and bolts of human cytomegalovirus lytic DNA replication.

G S Pari1.   

Abstract

HCMV lytic DNA replication is complex and highly regulated. The cis-acting lytic origin of DNA replication (oriLyt) contains multiple repeat motifs that comprise two main functional domains. The first is a bidirectional promoter element that is responsive to UL84 and IE2. The second appears to be an RNA/DNA hybrid region that is a substrate for UL84. UL84 is required for oriLyt-dependent DNA replication along with the six core proteins, UL44 (DNA processivity factor), UL54 (DNA polymerase), UL70 (primase), UL105 (helicase), UL102 (primase-associated factor) and UL57 (single-stranded DNA-binding protein). UL84 is an early protein that shuttles from the nucleus to the cytoplasm, binds RNA, suppresses the transcriptional activation function of IE2, has UTPase activity and is proposed to be a member of the DExH/D box family of proteins. UL84 is a key factor that may act in concert with the other core replication proteins to initiate lytic replication by altering the conformation of an RNA stem loop structure within oriLyt. In addition, new data suggests that UL84 interacts with at least one member of the viral replication proteins and several cellular encoded proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637505     DOI: 10.1007/978-3-540-77349-8_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  28 in total

1.  Role of the specific interaction of UL112-113 p84 with UL44 DNA polymerase processivity factor in promoting DNA replication of human cytomegalovirus.

Authors:  Young-Eui Kim; Jin-Hyun Ahn
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta.

Authors:  Cyprian C Rossetto; Ni Ketut Susilarini; Gregory S Pari
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 3.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

4.  Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

5.  Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

6.  Human cytomegalovirus IE2 86 and IE2 40 proteins differentially regulate UL84 protein expression posttranscriptionally in the absence of other viral gene products.

Authors:  Rebecca L Sanders; Deborah H Spector
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

7.  Host-viral effects of chromatin assembly factor 1 interaction with HCMV IE2.

Authors:  Sung-Bau Lee; Chung-Fan Lee; Derick S-C Ou; Kalpana Dulal; Liang-Hao Chang; Chen-Han Ma; Chien-Fu Huang; Hua Zhu; Young-Sun Lin; Li-Jung Juan
Journal:  Cell Res       Date:  2011-03-29       Impact factor: 25.617

8.  Differential role for host translation factors in host and viral protein synthesis during human cytomegalovirus infection.

Authors:  Erik M Lenarcic; Ben Ziehr; Gabe De Leon; Duane Mitchell; Nathaniel J Moorman
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

9.  Interaction of human cytomegalovirus pUL84 with casein kinase 2 is required for oriLyt-dependent DNA replication.

Authors:  Yang Gao; Gregory S Pari
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

10.  The ORF59 DNA polymerase processivity factor homologs of Old World primate RV2 rhadinoviruses are highly conserved nuclear antigens expressed in differentiated epithelium in infected macaques.

Authors:  A Gregory Bruce; Angela M Bakke; Courtney A Gravett; Laura K DeMaster; Helle Bielefeldt-Ohmann; Kellie L Burnside; Timothy M Rose
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.